Tag: targeted therapy
-
GSK Plans First-Line Jideytro Filing After 94% Response Rate
GSK plans to seek first-line FDA approval for Jideytro after the ROS1 inhibitor achieved a 94% response rate in 94 TKI-naïve patients in the ARROS-1 study.
-
How Daraxonrasib Blocks Active RAS Across Multiple Mutations
Daraxonrasib forms a cyclophilin A-dependent tri-complex with active RAS, blocking downstream signaling across multiple RAS variants.